FLT3 and acute myeloid leukemia: In vitro studies have shown that inhibition of FLT3-ITD by quizartinib/AC220 also downregulates FOXM1 expression in FLT3-mutated cells suggesting that FOXM1 may be a potential prognostic marker and therapeutic target in AML.